NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Pliant Therapeutics, Inc. PLRX
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.43
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-61.5%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 7-year series below
Revenue
Net income
Per share
USD -2.43
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-61.5%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-48.0%
Each USD of equity lost 62 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+72.8%
Change, 10 years—
The share count grew 73% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 225.2M
total assets, end of FY2025
Total assetsUSD 225.2M
EquityUSD 181.2M
CashUSD 45.4M
Gross debtUSD 0.00
Net debtUSD -45.4M
Current ratio12.00×
The company holds more cash than debt.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.1
Operating income $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−2.43
−3.47
−2.75
−2.94
−2.71
−1.95
−4.22
Dividend / sh $
0.00
0.00
0.00
0.00
0.00
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−61.5
−54.1
−41.0
−48.1
−40.3
−40.2
·
Shares out B
0.06
0.06
0.06
0.05
0.04
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed